The AI-enabled software automates whole-body tumor burden analysis for PSMA PET/CT and SPECT/CT studies to help clinicians assess treatment eligibility and monitor response.
GE HealthCare has received 510(k) clearance from the US Food and Drug Administration for MIM LesionID Pro, software designed to automate whole-body tumor burden analysis for PSMA PET/CT and SPECT/CT imaging studies.
The tool, part of GE HealthCare’s MIM software portfolio, uses AI-powered automation to help reduce the time and effort required for clinicians to evaluate tumor burden across the body. The analysis can support treatment planning and monitoring for patients receiving radiopharmaceutical therapy.
Theranostics—a personalized approach in nuclear medicine—combines diagnostic imaging with targeted therapy. In this setting, measuring total tumor burden can provide insight into disease status and treatment response, but the process has historically required manual, time-intensive analysis.
MIM LesionID Pro is designed to streamline that workflow. With one click, patient data is processed through the software to generate automated segmentation of PSMA uptake across the body, with normal physiological uptake removed for review. Clinicians can then review and edit the results to confirm quantitative total tumor burden measurements and evaluate disease progression over time.
“The FDA clearance of MIM LesionID Pro is a powerful step forward in our commitment to deliver intelligent, connected solutions that help clinicians make fast, confident decisions. By automating whole-body tumor burden analysis in PSMA PET/CT and SPECT/CT studies, this innovative digital tool simplifies a complex process and brings us closer to realizing the full potential of theranostics and personalized medicine,” said Jean-Luc Procaccini, president and CEO of molecular imaging and computed tomography, GE HealthCare, in a release. “It’s a clear example of how we’re advancing precision care—connecting insights across platforms to support smarter care delivery and enable better patient outcomes.”
According to the company, the software includes AI-powered segmentation through MIM Contour ProtégéAI+, which helps exclude physiological uptake during automated tumor burden analysis. It also provides visualization and reporting tools designed to help clinicians track disease changes over multiple therapy cycles and communicate findings with referring physicians and patients.
GE HealthCare says the new software supports its broader precision care strategy by combining imaging data, automation, and analytics to help clinicians make treatment decisions and monitor outcomes.
Photo caption: MIM LesionID Pro
Photo credit: GE HealthCare
